Project description
Novel highly efficient bladder cancer treatment with low toxicity
The ideal cancer treatment should combine great efficacy with high selectivity. The Swedish HAMLET Pharma AB develops revolutionary cancer treatments on a peptide-based platform for targeting and killing tumor cells with high precision. Their proprietary drug complex is derived from the human breast milk protein, alpha-lactalbumin, and represents a therapeutic solution with high tumor-killing capacity, high target specificity, no demonstrated toxicity, killing more than 40 different types of tumor cells. The EU-funded HAMLET-BC project will advance this drug complex in combination with the synthetic drug candidate Alpha1H into the clinical development pipeline as an early-stage treatment for bladder cancer, which has the highest recurrence rate among all cancer types.
Objective
Novel cancer treatments should ideally combine efficacy with selectivity. Tissue toxicity and side-effects are still the norm, however. Although new targeted therapies act with greater precision, the notion of tumour-specific cell death is justly regarded with scepticism. The Swedish company Hamlet Pharma provides new cancer treatments based on a peptide-based molecular approach for targeting and killing tumour cells with greater precision. Its proprietary drug complex, HAMLET (‘Human Alpha-lactalbumin Made LEthal to Tumour cells’) is derived from the human breast milk protein, alpha-lactalbumin, and represents a ground-breaking therapeutic solution with high tumour-killing capacity, high target specificity, killing >40 different types of tumour cells and no demonstrated toxicity. As such, it has the potential to revolutionize cancer treatment. Hamlet Pharma is now advancing HAMLET and the synthetic drug candidate Alpha1H along the clinical development pipeline as anti-cancer therapeutic for early stage bladder cancer. The company is focusing on bladder cancer given the high clinical need for more effective and safe treatment options. Bladder cancer has the highest recurrence rates (70%) and treatment costs per patient among all cancer types (total costs in Europe: >€4.9 billion). Recent successful outcomes include initial Phase I/II clinical trial data, proving that Alpha1H acts with high efficacy without any detectable toxicity. With the EIC Accelerator funding, Hamlet Pharma will finalise Phase I/II clinical safety and efficacy studies and advance development of Alpha1H towards a Phase III trial (i.e. ready for licensing deal or IPO). Conversations with potential licensing partners and investors are ongoing. Alpha1H will be an important showcase of the impact HAMLET will have on cancer treatment (expected cumulative revenues: €350M five years after market approval). Generated revenues will be reinvested into development of HAMLET for other cancer indications.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesclinical medicineoncologybladder cancer
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteins
You need to log in or register to use this function
Keywords
Programme(s)
Call for proposal
(opens in new window) H2020-EIC-SMEInst-2018-2020
See other projects for this callSub call
H2020-EIC-SMEInst-2018-2020-3
Funding Scheme
SME-2 - SME instrument phase 2Coordinator
222 42 Lund
Sweden
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.